International Coordination Group on Vaccine Provision for Epidemic Meningitis Control
Report of the Annual Meeting Geneva 13–14 July 2017
WHO/WHE/IHM/2017.15 © World Health Organization 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercialShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-ncsa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. International Coordination Group on Vaccine Provision for Epidemic Meningitis Control. Report of the annual meeting, Geneva, 13–14 July 2017. Geneva: meeting report: World Health Organization; 2017 (WHO/WHE/IHM/2017.15). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. This publication contains the report of the meeting of International Coordination Group on Vaccine Provision for Epidemic Meningitis Control and does not necessarily represent the decisions or policies of WHO.
iii
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
Table of contents List of abbreviations ................................................................................................................... iv Executive summary .................................................................................................................... v 1. Epidemiological update 2016–2017 ........................................................................................ 1 2. ICG response and performance .............................................................................................. 2 3. Stockpile update ..................................................................................................................... 5 4. Vaccine supply, procurement and forecasting......................................................................... 5 5. Evaluation of the ICG .............................................................................................................. 6 6. Discussion with manufacturers ............................................................................................... 7 7. Discussion .............................................................................................................................. 7 8. Action points ........................................................................................................................... 9 Annex 1. Agenda ...................................................................................................................... 11 Annex 2. List of participants ...................................................................................................... 13
List of tables Table 1. Summary of 2017 sub-Saharan meningitis outbreaks ................................................... 2 Table 2. ICG performance against targets .................................................................................. 2 Table 3. Summary of requests received, responses and performance, February–May 2017 ...... 3 Table 4. Summary of meningitis vaccine requests and shipments, 2016–2017 .......................... 5
List of figures Figure 1. Timeliness of outbreak responses, Nigeria, 2017 ........................................................ 2 Figure 2. Timeline for the ICG evaluation process ...................................................................... 6
iii
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
List of abbreviations AFRO EMRO EPI GAVI ICG Nm MSF PQ RF UNICEF SD WHO WHO Regional Office for Africa WHO Regional Office for the Eastern Mediterranean Expanded Programme on Immunization Gavi, the Vaccine Alliance International Coordinating Group Neisseria meningitides Médecins sans Frontières Prequalification Revolving Fund United Nations Children’s Fund Supply Division of UNICEF World Health Organization
iv
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
Executive summary International Coordinating Group (ICG) on Vaccine Provision for Meningitis held its annual meeting in Geneva from 13 to 14July 2017. The aim of the meeting was for partners and stakeholders to review: the 2016–2017 meningitis epidemic season in sub-Saharan Africa; the lessons learned from the 2017 the season; the composition and funding of the 2018–2020 stockpile; and the exchange of information with ICG partners and vaccine manufacturers. Participants included representatives of the World Health Organization (WHO) headquarters (HQ), including the ICG Secretariat, the WHO Regional Office for Africa (AFRO) and the WHO Regional Office for the Eastern Mediterranean (EMRO), the United Nations Children’s Fund (UNICEF), with participants from both HQ and the Supply Division (SD), Médecins sans Frontières (MSF), and the International Federation of Red Cross and Red Crescent Societies (IFRC). Other participants included representatives of Gavi, the Vaccine Alliance (GAVI), and a team of Hera consultants, which has been commissioned to evaluate the ICG. Representatives of vaccine manufacturers also attended the meeting in order to present their plans for current and future vaccine production and supply. Vaccine requests During the 2017 season, 4 208 505 doses of vaccine had been requested and 2 877 490 had been deployed (including 823 000 doses donated by the United Kingdom). The outbreak season was dominated by Neisseria meningitides (Nm) type C (Nm-C) and other non-Nm-A serogroups (Table 4). The ICG’s meningitis stockpile received 11 requests from five countries (Benin, Cameroon, Niger, Nigeria and Togo). Requests from Cameroon and Nigeria were fully approved, the request from Niger was partially approved, and two from Benin were not approved. Vaccine responses Factors were identified that had had an impact on the magnitude and timeliness of the response to the outbreaks. Vaccine supply is a significant issue related to the continuing global shortage, and the need for manufacturers to have appropriate production lead times and procurement commitments to better accommodate production planning, and reduce producer risk. The ICG underlined the need for an affordable polyvalent conjugate vaccine. A prompt response is essential to limit the extent of an outbreak. Multiple factors were identified which can cause delays at country level. These highlight the need for stronger epidemiological and laboratory reporting, and early access to technical assistance. Countries should submit the requested information in full to ensure the efficient processing and shipment of campaign vaccines, antibiotics and materials. Requesting authorities should consider in-country importation and logistics procedures as well as the capacity of national preparedness and response committees. v
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
The analysis of these delays revealed that they are usually beyond the control of the ICG, highlighting the need for performance indicators to reflect more accurately the specific and respective responsibilities of the different stakeholders involved in the response. Nevertheless, overall performance has improved, with a reduction in the average number of days from decision to reception from 13 days in 2016 to 9.8 days in 2017. Stockpile update UNICEF SD updated the meeting on its move towards a longer term planning approach to vaccine supply. ICG has requested 5 million doses per year to be available over the next four years. SD will announce a multi-year tender, for the period 2018–2021, now that the GAVI funds have been allocated. The new tender will be issued on 2 August 2017. Awards will be made for the full period and will take into consideration the ICG’s need for 5 million doses to be available for the start of each epidemic season. The ICG decided to replenish the stock of antibiotics for treatment by approving a new quantity of 70 000 vials of ceftriaxone to be made available by 1 January 2018.
vi
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
1. Epidemiological update 2016–2017 Meningococcal meningitis outbreaks remain a major public health burden in the 26 countries of the African ‘meningitis belt’. Six of the 12 described serotypes can cause outbreaks (A, B, C, W135, X and Y). During the 2016–2017 meningitis outbreak season in sub-Saharan Africa, four major pathogens were reported from six national outbreaks. The most significant was Neisseria meningitides (Nm) type C (Nm-C), which was detected in Benin, Cameroon and Liberia. The largest outbreaks of the season were in Niger and Nigeria. In Nigeria, a cumulative total of 14 518 cases and 1166 deaths were reported (Table 1). Laboratory investigations were completed for 998 cases, of which 460 (47%) were confirmed as bacterial meningitis. Among those who tested positive, 81% were identified as Nm-C. Cases were reported from 25 states: the most affected being Katsina, Sokoto and Zamfara. Children aged 5–14 years accounted for 47% of reported cases. As the outbreak season progressed there was a steady decline in new cases reported, from a peak of approximately 2500 cases per week in epidemiological weeks 14–15 to 80 in epidemiological week 22. Sporadic cases of meningitis were identified in Niger from the beginning of 2017. By 19 March 2017, seven districts were on alert and an outbreak was officially declared on 29 March 2017. By 31 May 2017, 2796 samples of cerebro-spinal fluid (CSF) had been tested, of which 1607 were positive: 66.9% were identified as Nm-C, 17.2% as Nm serogroup X, 10.3% as Nm and Streptococcus pneumoniae, and 5.6% classified as ‘other’. Although cases were reported throughout the country, Dosso, Maradi, Niamey, Tahoua and Tilaberi were the most affected regions accounting for 98% of cases. Free treatment with ceftriaxone was provided in all health centres according to WHO protocols. As with Nigeria, the weekly number of new cases being reported steadily declined so that by 4 June 2017, there were four new suspected cases, and all districts were below epidemic or alert status. By 8 June 2017, there had been a total of 3303 suspected cases, with 197 deaths, and a confirmed fatality rate (CFR) of 6%. Nm type W135 (Nm-W) was the predominant pathogen in Togo, where 1975 suspected cases and 125 deaths were reported. However, in the laboratory-confirmed cases in Niger, Togo and Chad outbreaks, Nm-X was also detected in 40%, 17% and 9%, respectively, of the laboratoryconfirmed cases. Between January and June 2017, throughout the meningitis belt, 18% of laboratory-confirmed cases were identified as S. pneumoniae, and, in Ghana, in three of the four affected districts, it accounted for 50% of cases.
1
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
Table 1. Summary of 2017 sub-Saharan meningitis outbreaks
Country
Suspected cases
Deaths
Confirmed fatality rate (%) 8 6 6.6 36 9.2 9.3
Nigeria Niger Togo Cameroon Ghana Chad
14 513 3 303 515 25 817 205 (18 Nm-X)
1 166 197 35 9 75 ND
ND: not determined.
2. ICG response and performance The following figure shows ICG performance in relation to its targets. Table 2. ICG performance against targets
Average in days (target in days) Reception to circulation 0 (1) Additional information submitted 0.7 (N/A) Decision Decision to reception 9.8 (7) Vaccination starts
1.1 (2)
6.8 (N/A)
N/A: not applicable.
The monitoring and evaluation of ICG’s performance raised concern because, as currently framed, the key performance indicators do not necessarily reflect ICG members’ specific responsibilities and actions since their achievement depends upon factors beyond their control, such as delays at customs, regulatory approvals, and the shipment of vaccines to the countries, etc. Figure 1 illustrates this concern and is taken from a review of experience across four states in Nigeria. The review reported a range of 31 days (Sokoto) to 51 days (Zamfara) between making a request to ICG and the preparation of the campaign. The most significant delays occurred in the former and in vaccine delivery, both of which are beyond the control of the ICG. Similar patterns were found in Cameron and Togo, from between 20 days and 38 days, respectively. Figure 1. Timeliness of outbreak responses, Nigeria, 2017 2
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
Table 3. Summary of requests received, responses and performance, February–May 2017 Country Reception to circulation Same day Additional information submitted by country 1 day Decision Decision to reception 16 days Vaccination starts after reception 4 days Number doses released 56 000 Comment
Togo
1 day
Cameroon Nigeria Togo
Same day Same day Same day
1 day Same day N/A
1 day 1 day 1 day
9 days 7 days 10 days
1 day 9 days 8 days
7 200 500 000 120 000
Niger Nigeria
Same day Same day
Same day N/A
1 day 1 day
4 days 14 days
11 days 3 days
341 140 823 970
Delay due to 8–10 dose a vials – – WHO Country Office postponed delivery from Friday to Monday – Reduced availability of staff because of holiday weekend
3
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017 Benin Niger Nigeria Same day Same day Same day – N/A 1 day 2 days 2 days 1 day – 5 days 16 days – 11 days 2 days – 145 600 189 280 Not approved Partially approved Difficulties in obtaining correct consignee information Pfizer 8–10 dose issue – Not approved
Nigeria Benin
Same day Same day
1 day N/A
1 day 2 days
7 days –
12 days –
694 300 –
N/A: not applicable. a UNICEF SD advised that 8 doses per vial presentation were going to be procured when ultimately the country only received 10 doses per vial.
The average time from ICG’s decision to reception of vaccine in-country has decreased from 13 (2016) to 9.8 days. An analysis of specific delays in the process highlighted the respective roles and responsibilities of the ICG Secretariat, UNICEF’s SD and requesting countries. For example, the two requests from Benin failed because of delays in-country in providing essential information (despite repeated requests from the ICG Secretariat), and the late submission of the request in relation to the epidemic. A two-day delay in Nigeria was caused by the time it took to provide MSF with a correct consignment number. The delay in supplying Togo’s first request occurred because UNICEF’s SD had cancelled a purchasing order from Pfizer because of the number of vials per package, i.e. eight rather than the standard 10 doses. The second request from Togo was also delayed, this time because of an in-country decision to postpone delivery until after the weekend. It was proposed that performance indicators should be revised to reflect the respective responsibilities of the ICG, UNICEF’s SD, countries and requesting partners, i.e. ICG (requests review and decisions); UNICEF’s SD (delivery of vaccines to countries); countries and requesting partners (implementation, including coverage surveys). In response to the requests for greater transparency, the ICG Secretariat drew attention to the dashboards and interactive maps that have been uploaded onto the WHO website for each stockpile and their contribution to increased transparency of currently available vaccines and the activity of the respective stockpiles. The links to the meningitis dashboard and interactive map are given below: http://www.who.int/csr/disease/icg/meningitis-dashboard/en/ http://www.who.int/csr/disease/icg/meningitis-interactive-map/en/ UNICEF’s SD has also created dashboards for stockpile vaccine availability: https://www.unicef.org/supply/files/Emergency_Stockpile_Meningococcal.pdf
4
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
3. Stockpile update GAVI provided an update on its work for a new meningitis roadmap (to be completed by the end of 2017), forecasting strategic demand scenarios which is intended to inform GAVI’s supply and procurement roadmap and vaccine investment strategy. UNICEF SD updated the meeting on its move towards a longer term planning approach to vaccine supply. ICG has requested 5 million doses per year to be available over the next four years. SD will announce a multi-year tender, for the period 2018–2021, now that the GAVI funds have been allocated. The new tender will be issued on 2 August 2017. Awards will be made for the full period and will take into consideration the ICG’s need for 5 million doses to be available for the start of each epidemic season. During the lifetime of any award, additional requests may be made for increased production in response to need, which in turn anticipates flexibility on the part of manufacturers to deliver additional doses in response to emerging needs. Partners and stakeholders welcomed UNICEF SD’s commitment to long-term planning, but expressed considerable concern that this has resulted in insufficient notice to meet the anticipated requirements of coming epidemic seasons. The procedures described did not respond to the specific needs when responding to meningitis, which is more complex than either yellow fever or cholera. Given the number of vaccine manufacturers, especially of polysaccharides, leaving the market, ICG members asked that a specific approach be taken by SD to ensure that manufacturers have firm commitments in time for them to launch the manufacturing process. If this is not the case, ICG members suggested that the Revolving Fund (RF) could be used to procure vaccines.
4. Vaccine supply, procurement and forecasting During the 2017 meningitis outbreak season, 11 requests were received from five countries. Two requests from Benin were not approved because the epidemic threshold was not reached and the responsible pathogen had not been identified. A request from Niger was partially approved. All other requests were approved in full. A total of 2 877 490 vaccine doses have been shipped so far this year, compared to 1 097 000 in 2016. Table 4. Summary of meningitis vaccine requests and shipments, 2016–2017
Year
Meningitis vaccine requested 2 238 818 4 208 505
Meningitis vaccine shipped 1 097 000 2 877 490
2016 2017
The vaccine available for the 2017 stockpile was below the quantity recommended by the ICG in July 2016 of 5 million doses. Only 2.1 million doses were available. 5
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
The ICG decided to replenish the stock of antibiotics for treatment by approving a new quantity of 70 000 vials of ceftriaxone to be made available by 1 January 2018. A new tender should be issued as other suppliers may offer better conditions. Independently of the offers, it was agreed that is always preferable to have some quantities in Geneva for quick deployment. It was decided to bring 20 000 vials and keep 50 000 as a rotating stock.
5. Evaluation of the ICG Consultants representing Hera, the company contracted to conduct an external evaluation of the ICG, observed the meeting and presented on its purpose and progress. The evaluation was commissioned with a view to improving the governance of the ICG, and mechanisms related to its management and accessibility to disease-specific, emergency stockpiles and their composition, the transparency of ICG decision-making processes, and internal and external communication. The specific objectives of the evaluation are: to highlight the strengths and weaknesses of ICG’s governance, effectiveness, efficiency and transparency of decision-making, funding and management; and to develop actionable options and recommendations for improving the functioning of the ICG and the ICG mechanism. The evaluation is based upon documentation reviews, key informant interviews, case studies of outbreak responses and social network analyses, together with online surveys among both ICG stakeholders and applicants. The anticipated timeline of the evaluation process is as follows in Figure 2. Figure 2. Timeline for the ICG evaluation process
Source: Hera.
6
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
6. Discussion with manufacturers The ICG had forecasted the need for 5 million doses of whole cell (WC) containing vaccines for 2018. However, the producers confirmed the projected vaccine availability significantly lower than 5 million. The ICG members met separately to discuss the possibility of using the RF to immediately procure vaccines. Key challenges exist in terms of synchronizing timelines between the tendering and manufacturing process. For the manufacturers to be able to deliver increased production, a minimum lead-time is required, which is not always provided. Vaccine demand is highly outbreak-dependent rather than predictable for mass vaccination campaigns (e.g. yellow fever) and only a small portion is reserved for outbreak response. In the absence of sufficient lead times and confirmed orders, additional production of meningitis vaccine increases the risk for producers. For example, in February 2017, Finlay produced 152 000 doses in response to a UNICEF request. The contract was not signed until nearly four months later.
7. Discussion Salient points discussed during the meeting are listed below. Predominance of non-Nm-A serogroups: The predominant pathogen identified from outbreaks during the 2016–2017 season was Nm–C. The continued emergence and spread of Nm-C is unknown. Nm-W135, X and S. pneumoniae also accounted for a significant number of cases. Timeliness of response: To limit the impact of an outbreak, the vaccination campaign should be completed as soon as possible. Once the epidemic threshold is crossed, the benchmark from the ICG request, to completion of the campaign should be 28 days. Various elements contributed to delays including, reporting of cases, completion of ICG requests, shipment of vaccine, in-country clearance and logistics. Surveillance: Epidemiological, laboratory and data strengthening to facilitate timely reporting and response. management components need
Preparedness: National preparedness and response committees and regional technical coordination need to be reactivated and strengthened. Vaccine supply: The global shortage of vaccine for outbreak response continues. The transition from polysaccharide to conjugate vaccines has critically reduced the number of producers. Vaccine procurement: Manufacturers require substantial lead times, and the production of vaccine without firm commitments to procure presents them with substantial risk. The 7
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
procurement process and available stockpile vaccine did not meet ICG timelines and required estimates, which directly influenced vaccine deployment decisions in terms of magnitude and target age groups. Finite stockpile vaccine: The reduced availability of vaccine requires that they be strategically deployed to maximize the impact on an outbreak. Unused campaign vaccine needs to be identified in a timely manner. Case management: This was identified as a weak technical component with critical challenges in terms of availability and accessibility of ceftriaxone. Shipments were delayed at Nigerian customs where 20 000 doses were held for more than a month. The availability of ceftriaxone within Nigeria is limited and antibiotics are not provided of free of charge. First use monovalent conjugate vaccine: A donation from the United Kingdom of conjugate monovalent Nm-C vaccine was used in a reactive campaign for the first time in Africa. Fake vaccines: During vaccine campaign responses, fake and non-prequalified vaccines were found in circulation and on sale to the public. Meningitis A conjugate: The impact of the continuing introduction of Men-A conjugate is reflected in vaccinated areas. Mass campaigns are planned for 2018, and a programme for routinely introducing the vaccine will be organized during 2019. Affordable multivalent conjugate vaccine: The development of an affordable multivalent conjugate vaccine is a priority to resolve the vaccine shortages for sub-Saharan Africa.
8
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
8. Action points No. Action point 1 ICG Secretariat will strongly encourage countries to prepare and include independent vaccine coverages surveys as part of their vaccination plans and budgeted operational costs. If necessary, GAVI’s costing template should be adjusted accordingly to reflect this. 2 WHO to convene a technical consultation to consider when the response to pneumococcal outbreaks should include emergency vaccination. 3 Nigeria’s Ministry of Health to provide formal confirmation to ICG of the current status, locations and plans for remaining vaccine (Neisvac C) from the United Kingdom. 4 AFRO and the Country Office in Nigeria to work with the Ministry of Health to anticipate and address factors known to delay the release of goods from customs when outbreak occurs. 5 AFRO and the Country Office in Nigeria should also work with the national authorities to review case management practices, including the use of antibiotics. 6 UNICEF SD to share with ICG, as soon as possible, information on likely numbers of vaccines available in January 2018, in anticipation of the September planning meeting for African countries in Ouagadougou. Encourage GAVI to consider whether existing pneumococcal conjugate vaccine (PCV) available in-country for routine expanded programmes on immunization (EPI) could be used for outbreak responses. Responsible ICG Secretariat/countries When December 2017
WHO meningitis team
By Dec 2018
WHO AFRO Government of Nigeria
As soon as possible
AFRO, WHO Country Office, Ministry of Health
To be addressed before next epidemic season
AFRO, WHO Country Office, Ministry of Health, and other relevant ministries UNICEF SD
To be addressed before next epidemic season
As soon as possible
7
WHO meningitis team, GAVI
Dec 2017
9
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
8
9
10
11
12 13
14
15
Replenish stock of antibiotics up to 70 000. UNICEF SD to confirm with Pfizer and GlaxoSmithKline (GSK) whether 8-dose packs are still in circulation and, if so, where? UNICEF should work with Pfizer and GSK to improve delivery time in line with the ICG’s requirements. Similarly, UNICEF should work with SanofiPasteur, USA. WHO to invite manufacturers to Ouagadougou meeting. Country preparedness plans need to include the improvement of surveillance and laboratory capacity to identify Nm-X.* Encourage suppliers (e.g. Chinese manufacturer Hualan and Walvax) to respond and prepare for prequalification. UNICEF to consider the feasibility of an emergency tender to address the shortfall in the 2018 stockpile. When ICG evaluation is complete, the performance indicators should be reviewed and revised to reflect respective organizational responsibilities, ensuring indicators are an appropriate and suitable measure: ICG – reviews requests and decisions UNICEF SD – deliveries of vaccines to countries countries and requesting partners – implementation including coverage survey. UNICEF SD should confirm to ICG the number of doses secured for 2018.
WHO UNICEF SD
January 2018 As soon as possible
UNICEF SD
Before next epidemic season
WHO WHO AFRO
September 2017 September 2017
WHO, ICG Secretariat
In the next 2 years
UNICEF SD
As soon as possible
WHO
Dec 2017
16
UNICEF SD
May 2018
* Neisseria meningitides serogroup X.
10
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
Annex 1. Agenda Objectives: Review the 2016–2017 meningitis epidemic season in sub-Saharan Africa Discuss lessons learned from 2017 season Discuss the 2018–2020 stockpile size, composition and funding Exchange information with extended ICG partners and vaccine manufacturers DAY 1 Session 1. Supply issues and stockpile forecasting Time 08:30–10:45 Arrival of participants Opening remarks Epidemic season 2017 Challenges in outbreak response Pneumococcal meningitis in Ghana – need for stockpile? Meningitis A update 10:45–11:00 11:00–11:30 Coffee break ICG performance indicators, 2017 Topic – Alejandro Costa, WHO André Bita/Clément Lingani, WHO, AFRO Olivier Ronveaux, Katya Fernandez, WHO HQ Fernanda Lessa, CDC Marie-Pierre Preziosi, WHO All Alexandra Hill, WHO, Guillermo Gimeno, UNICEF SD Miriam Alia, MSF Dorothy Nwodo, National Primary Health Care Development Agency (NPHCDA) UNICEF SD and ICG Secretariat ICG Secretariat Presenter
11:30–11:40 11:40–12:10
Challenges in vaccination campaign in Nigeria (Yobe State) Analysis of time delays/costs of delays and lessons learned in Nigeria
12:10–13:00
Stockpile levels Supply issues with stockpile, 2017
13:00–14:00 14:00–14:45
Lunch discussion: Revolving Fund – current status Closed session and future Discussion on lessons learned and action points All 11
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
14:45–15:45
Stockpile 2018–2022, strategic decision, forecast, Alejandro Costa, WHO and vaccine procurement strategy to increase vaccine UNICEF SD availability and tender update
15:45–16:00 16:00–16:30 16:30–17:30 17:30–18:30 DAY 2
Coffee break Market shaping 2019–2020 meningitis vaccine forecast group Discussion on stockpile 2018–2022
All GAVI All
Reception
All – cafeteria
Session 2. Update of partners regarding ICG decisions and presentations from manufacturers Time 9:00–10:30 Topic Presenter
ICG evaluation Hera Processes to increase transparency of UNICEF UNICEF SD SD and WHO dashboards ICG Secretariat Meningitis outbreaks and surveillance, 2017 AFRO/EMRO focal points All GAVI Bio-Manguinhos/Finlay GSK Pfizer Sanofi-Pasteur Serum Institute of India Hualan Bio-Med Walvax All All All
10:30–11:00 11:00–11:30 11:30–13:00
Coffee break (group picture) Market shaping 2019–2020 meningitis vaccine forecast group Manufacturers production forecast 2018–2022
Discussion 13:00–14:00 14:00–14:30 Lunch Conclusions
12
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
Annex 2. List of participants ICG Executive Members 1 Myriam Henkens 2 Miriam Alia 3 Robert Kezaala 4 Imran Mirza 5 Amanda McClelland 6 Tiina Saarikoski 7 Panu Saaristo 8 Olivier Ronveaux 9 Katya Fernandez ICG Secretariat 10 Alejandro Costa 11 Alexandra Hill 12 Stephen Martin 13 Tim Nguyen WHO staff 14 Mamoudou Djingarey* 15 Linda Awa Omar 16 Ifeanyi Okudo 17 Amgad Abdalla Elkholy 18 Sylvie Briand 19 William Perea 20 Marie-Pierre Preziosi 21 André Bita 22 Clément Lingani Manufacturers** 23 Denise Maria Lobo Crivelli 24 Patricia Corrêa Santana 25 Francisco Dominguez 26 Francoise Griguer 27 Marc Laforce 28 John Roberts 29 John Musanga* 30 Guoliang Fang 31 Shuyuan Yang 32 Jing Wang 33 Cai Linlin (Kevin)* 34 Pan Ruowen* 35 Saryu Garg* Other meningitis partners
MSF MSF UNICEF UNICEF IFRC IFRC IFRC WHO WHO WHO WHO WHO WHO WHO/AFRO WHO/AFRO WHO/CO/Nigeria WHO/EMRO WHO/HQ WHO/HQ WHO/HQ WHO/CO/AFRO WHO/CO/AFRO Bio Manguinhos Bio Manguinhos Finlay Sanofi Pasteur SII Pfizer GSK Walvax Walvax Walvax Hualan Biological Hualan Biological Bio-Med
myriam.henkens@msf.org miriam.alia@barcelona.msf.org rkezaala@unicef.org imirza@unicef.org amanda.mcclelland@ifrc.org tiina.saarikoski@ifrc.org panu.saaristo@ifrc.org ronveauxo@who.int fernanadezk@who.int costaa@who.int hilla@who.int martins@who.int nguyent@who.int djingareyh@who.int hajl@who.int okudoi@who.int elkholya@who.int briands@who.int pereaw@who.int preziosim@who.int bitaa@who.int linganic@who.int Dlobo@bio.fiocruz.br patricia.santana@bio.fiocruz.br fdominguez@finlay.edu.cu Francoise.Griguer@sanofipasteur.com fmarclaforce@gmail.com John.Roberts@pfizer.com John.2.musunga@gsk.com yxwsfgl@walvax.com ynwsysy@walvax.com 78595413@qq.com cll1930@163.com xxprw@163.com saryugarg@yahoo.com
13
International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control meeting, July 2017
36 Michael Thomas GAVI mthomas@gavi.org 37 Melissa Ko GAVI mko@gavi.org 38 Edward Baker GAVI ebaker@gavi.org 39 Matthew Blakley GAVI mblakley@gavi.org 40 Margarita Xydia-Charmanta GAVI mxydiacharmanta@gavi.org 41 Stephen Sosler GAVI ssosler@gavi.org 42 Guillermo Gimeno UNICEF SD ggimeno@unicef.org 43 Ryan T. Novak CDC bnk4@cdc.gov 44 Fernanda Lessa CDC dta3@cdc.gov 45 Andrew Jones Gates foundation Andrew.Jones@gatesfoundation.org 46 Dorothy Nwodo NPHCDA dnnwodo@outlook.com 47 Claire Giron AFD gironc@afd.fr Rapporteur 48 Peter Gordon Consultant petergordon@blueyonder.co.uk Others 49 Leen Jille LAUCO Evaluation & Training Leen.Jille@hera.eu 50 Marieke Devillé LAUCO Evaluation & Training Marieke.Deville@hera.eu
14